Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Langenbeck'S Archives of Surgery|December 25, 2016
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinomaGencay Hatiboglu, Markus Hohenfellner, Aysenur Arslan, et al.
Oncotarget|June 2, 2018
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing diseaseStefanie Zschäbitz, Florian A Distler, Benjamin Krieger, et al.
Oncotarget|November 2, 2017
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapySteffen Dietz, Holger Sültmann, YueJun Du, et al.
BMC Cancer|June 3, 2014
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trialFalk Roeder, Burkhard Lehner, Thomas Schmitt, et al.
Urologic Oncology|June 12, 2018
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancerCarine Pecqueux, Aysenur Arslan, Martina Heller, et al.
Oncotarget|February 5, 2019
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostateLeonidas Apostolidis, Cathleen Nientiedt, Eva Caroline Winkler, et al.
Scientific Reports|July 6, 2017
Mutations in BRCA2 and taxane resistance in prostate cancerCathleen Nientiedt, Martina Heller, Volker Endris, et al.
International Journal of Cancer|October 29, 2025
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARATPeter J Goebell, Martin Bögemann, Arnd Nusch, et al.
British Journal of Cancer|July 3, 2018
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trialAnne Katrin Berger, Stephan Lücke, Ulrich Abel, et al.
Translational Oncology|December 23, 2015
Prognostic Significance and Functional Role of CEP57 in Prostate CancerJosef Mang, Nina Korzeniewski, Dimo Dietrich, et al.
Pageof 7